Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

5-FLUOROURACIL AND 1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA (CCNU) FOLLOWED BY HYDROXYUREA, MISONIDAZOLE, AND IRRADIATION FOR BRAIN-STEM GLIOMAS - A PILOT-STUDY OF THE BRAIN-TUMOR RESEARCH-CENTER AND THE CHILDRENS CANCER GROUP NEUROSURGERY Levin, V. A., Edwards, M. S., Wara, W. M., Allen, J., Ortega, J., VESTNYS, P. 1984; 14 (6): 679-681

Abstract

Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole. The treatment was well tolerated, and minimal toxicity was produced. The median relapse-free survival was 32 weeks, and the median survival was 44 weeks. Analysis of covariates showed that, in patients between the ages of 2 and 19 years, survival was longest in the older children (P less than 0.02). Tumor histology, sex, extent of operation (if any), Karnofsky score, and radiation dose did not correlate with survival.

View details for Web of Science ID A1984TB47300006

View details for PubMedID 6087193